Combinib 250 mg Lapatinib IP is a targeted anti-cancer medication manufactured by Cipla. Primarily used to treat advanced or metastatic HER2-positive breast cancer, it is a tyrosi…
Combinib 250 mg Lapatinib IP is a targeted anti-cancer medication manufactured by Cipla. Primarily used to treat advanced or metastatic HER2-positive breast cancer, it is a tyrosine kinase inhibitor that blocks abnormal proteins driving cancer cell growth, often prescribed alongside capecitabine, trastuzumab, or hormonal therapies.
liketo.usa,uk,china,southkorea,russia,japan,singapore
Strength 250 mg
Packaging Size 30 Tablets
Pack Size 30 Tablets
Usage Breast Cancer
Manufactured By Cipla
Prescription/Non Prescription Prescription
Country of Origin Made in India
Composition Lapatinib Tablets IP
Brand Combinib
Form Tablet
Minimum order quantity: 50 Bottle
Composition details not available.
We offer reliable delivery across India and international markets. Domestic orders typically arrive within 5–7 business days. International shipping times vary by destination. All orders are carefully packaged to maintain product integrity and quality.
